Volume 25, Number 1A, pages 101-106: In all of the experiments in which flavopiridol was
used, the concentrations were in nanomolar and not micromolar. The concentrations of all of …

Flavopiridol is a synthetic flavonoid inhibitor of cyclin-dependent kinases, which is under
development by Aventis Pharma (formerly Hoechst Marion Roussel) and the National …

A high-performance liquid chromatographic assay with tandem mass spectrometric
detection was developed and validated for quantitation of the broad spectrum kinase …

Flavopiridol is an inhibitor of cyclin‐dependent kinase, a key regulator of cell cycle, and is
currently under clinical trials. We developed and validated an HPLC assay method for the …

Hoechst is developing flavopiridol, a synthetic flavonoid based on an extract from an Indian
plant, for the potential treatment of cancer. Flavopiridol, a cyclin-dependent kinase inhibitor …

Background Flavopiridol, a novel flavone derivative, inhibits cyclin-dependent kinase-1. We
initiated a Phase I trial in patients with refractory solid tumors to determine the maximum …

Purpose: Flavopiridol is a flavone which inhibits several cyclin-dependent kinases, and
exhibits potent growth-inhibitory activity against a number of human tumor cell lines both in …

A specific, sensitive, and simple high-performance liquid chromatographic method has been
developed for assaying flavopiridol in rat serum for preliminary bioavailability and …

Flavopiridol [5, 7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6′-chloroflavone
hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous …

Flavopiridol has shown promising activities in hematologic and solid tumor models, as well
as in clinical trials in chronic lymphocytic leukemia patients. Flavopiridol has relatively low …